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Lymphangioleiomyoma is a benign neoplasm of 
lymphatic vessels characterized as a PEComa 
(perivascular epithelioid cell tumour), involving the 
proliferation of epithelioid cells, with mutations in the 
tuberous sclerosis complex (TSC) genes TSC1 and 
TSC2. 
Clinics and pathology 
Note 
Lymphangioleiomyomas are commonly associated with 
lymphangioleiomyomatosis (LAM), a multi-system 
disorder primarily affecting women of child-bearing 
age. Initial presentation of LAM may  
result from pulmonary or extrapulmonary lesions. 
Pulmonary LAM is characterized by thin-walled cysts, 
which are diffused throughout the lungs. Patients wi h 
these lesions experience deterioration of lung functio  
that can lead to oxygen depen-dency, lung 
transplantation or death. Extrapul-monary LAM 
involves the axial lymphatics of the abdomen and 
thorax (lymphangioleiomyomas, adenopathy), and 
abdominal organs, especially the kidneys 
(angiomyolipomas). 
Abdomino-pelvic lymphangioleiomyomas may present 
with abdominal pain as an acute abdomen, with a 
neuropathy or with abdominal bloating. Thoraco-
abdominal lymphadenopathy and lymph-
angioleiomyomas, along with chylothorax (Figure 1) or 
ascites may suggest the presence of a malignant 
lymphoproliferative disease. 
 
Figure 1: Large left chylous pleural effusion (white arrow) in a patient with LAM. 
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Figure 2 A, B, C, D, and E. Histological characterization of extrapulmonary LAM. LAM cells form fascicles separated by lymphatic 
channels (A). (HE, original magnification x 100) An example of LAM cells arranged in trabecular bundles and irregular papillary patterns 
(B). (H&E, original magnification x 250) Image representing morphological heterogeneity of LAM cells; large epithelioid LAM cells 
(asterik) and smaller, round to oval cells (arrows) (C). (H&E, original magnification x 1,000) Positive reactivity of LAM cells to HMB-45 
(D). (immunoperoxidase with hematoxylin counterstain, original magnification x 400) Positive reactivity of LAM cells to SMMHC (E). 
(original magnification x 400). (from Matsui et al., Hum Pathol. 2000 October;31(10):1242-1248). 
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Etiology 
LAM results from proliferation of an abnormal cell, 
termed the LAM cell. LAM occurs in 30-40% of 
patients with tuberous sclerosis complex, an autosomal 
dominant disorder associated with mutations in the 
TSC1 or TSC2 genes. Sporadic LAM is caused 
presumably by cells with mutations of the TSC2 gene. 
Lymphatic involvement (including 
lymphangioleiomyomas) occurs less frequently in 
patients with LAM/TSC, than in patients with sporadic 
LAM. 
Epidemiology 
Lymphangioleiomyomas are present in about 16-21% 
of patients with LAM. 
Pathology 
Histological examination of the cells lining the walls of 
the extrapulmonary lesions reveal common 
characteristics with pulmonary LAM cells, abnormal 
smooth muscle-like cells with a mixture of epithelioid 
and splindle-shaped morphologies. Cells react with 
HMB-45, a monoclonal antibody against gp100 (a 
premelanosomal marker), and with antibodies against 
SMMHC, a smooth muscle-cell marker. Unlike the 
nodular collections of the pulmonary LAM cells, the 
extrapulmonary cells usually form fascicles or papill ry 
patterns. Both types of lesions contain slit-like 
lymphatic channels (Figure 2A, B, C, D, and E). 
Radiologic Imaging: Retroperitoneal lymphangio-
leiomyomas have a distinctive radiologic appearance 
(Figures 3-7), and diurnal variation in size of theumor 
masses can be demonstrated by ultrasonography or 
computed tomography scans (Figure 8).  
Lymphangioleiomyomas are well characterized by 
either ultrasonography or computed tomography 
scanning, appearing as well-circumscribed lobular, thin 
or thick-walled masses without evidence of necrosis r 
hemorrhage. Masses greater than 3 cm in diameter are 
usually cystic in appearance and many contain fluid, 
presumably chyle. Lesions as large as 20 cm in 
diameter have been observed. In patients with LAM, 
the lesions most often occur in the retroperitoneal 
region. 
Treatment 
There is no effective treatment for lymphangio-
leiomyomas. The lesions are usually asymptomatic, 
however, ascites, peripheral edema, and compres-sion 
of the bladder, bowel, pelvic veins and other viscera by 
large lymphangioleiomyomata may cause severe 
symptomatology, including pain, obstipation, urinary 
frequency, and peripheral edema. Although surgery is 
sometimes contemplated to ameliorate symptoms 
caused by visceral compression, it is contraindicated, 
as, in our experience; it may lead to persistent 
lymphatic  
leakage and intractable chylothorax and ascites. 
Chylous effusions including pleural effusions are 
particularly difficult to treat. Repeated thora-centeses 
lead to malnutrition and may result in infectious 
complications. Low fat diet with medium-chain 
triglycerides and therapeutic thora-centesis should be 
attempted initially. However, most patients require 
pleurodesis, which may be effective if the rate of chyle 
generation can be reduced. Patients should be placed on 
a fat-free parenteral nutrition regimen prior to, during, 
and after surgery. It is essential that good lung 
expansion be obtained to ensure complete apposition of 
the visceral and parietal pleura to avoid residual pleural 
pockets. After a successful pleurodesis, a low fat die
with mid-chain trigly-cerides is recommended. A 
peritoneal-venous shunt may be considered for most 
severe cases when the ascites is disabling and is 
causing mechanical/ nutritional problems, but little 
experience with this therapeutic modality in LAM is 
reported. Treatment with octreotide may be considere  
for those patients with disabling ascites and large 
lymph-angioleiomyomata. Previous studies with 
somato-statin and octreotide in other clinical settings 
(e.g., traumatic damage to the lymphatics, yellow nail
syndrome) have shown a successful reduction in 
chylous effusions, chyluria, ascites, and peripheral 
lymphedema.  
Sirolimus: The TSC1 and TSC2 genes encode 
respectively, hamartin and tuberin. Although Hamartin 
and tuberin may have individual functions, they are 
also known to interact in a cytosolic complex. 
Hamartin may play a role in the reorganization of the
actin cytoskeleton. Tuberin has roles in pathways 
controlling cell growth and proliferation. It is a 
negative regulator of cell cycle progression, and loss of 
tuberin function shortens the G1 phase of the cell cycle. 
Tuberin binds p27KIP1, a cyclin-dependent kinase 
inhibitor, thereby preventing its degradation and 
leading to inhibition of the cell cycle. Tuberin also 
integrates signals from growth factors and energy 
stores through its interaction with mTOR (mammalian 
target of rapamycin). Tuberin has Rheb GAP (Ras 
homolog enriched in brain GTPase-activating protein) 
activity, which converts active Rheb-GTP to inactive 
Rheb-GDP. Rheb regulates mTOR, a serine/threonine 
kinase that phosphorylates at least two substrates: 4E-
BP1, allowing cap-dependent translation, and S6K1, 
leading to translation of 5' TOP (terminal 
oligopyrimidine tract)-containing RNAs. 
Phosphorylation of tuberin by Akt, which is activated 
by growth factors, leads to inhibition of tuberin, 
resulting in cell growth and proliferation. 
Phosphorylation of tuberin by AMPK (AMP-activated 
kinase) activates tuberin and further promotes 
inhibition of cell growth in conditions of energy 
deprivation. 
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Figure 3. Mediastinal lymphangioleiomyoma (white arrow), located posteriorly to the descending thoracic aorta. A: aorta. 
Figure 4. Mediastinal lymphangioleiomyomas (white arrow), located posteriorly to the trachea.  
Figure 5. Large retroperitoneal lymphangioleiomyoma (white arrow) surrounding the aorta and inferior vena cava. A: aorta; IVC: inferior 
vena cava. 
Figure 6A and B. Black arrows point to large pelvic lymphangioleiomyoma (A). A complex lymphangioleiomyoma is shown marked by 
circle on panel B.  
Figure 7A, B and C. Evidence of bladder and bowel compression caused by the tumors. B: bladder. 
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Figure 8A, B, C and D. Diurnal variation of lymphangioleiomyomas. Abdominal ultrasound shows that the size of a lymphangioleiomyoma 
is greater in the evening (panel B) that in the morning (panel A). Abdominal CT scan showing also diurnal variation in tumor size from 
morning (panel C) to evening (panel D). 
 
Sirolimus, an inmmunosuppressive agent, inacti-vates 
mTOR. Sirolimus has been shown to induce apoptosis 
of tumors in rodents and decrease the size of renal 
angiomyolipomas in patients with lymph-
angioleiomyomatosis or TSC. Further, sirolimus was 
effective in decreasing the size of chylous effusion  and 
lymphangioleiomyomas in one patient with LAM and 
improved chylous effusions in another patient who 
underwent lung trans-plantation. 
Evolution 
Lymphangioleiomyomas are thought to occur due to 
the proliferation of LAM cells in lymphatic vessels, 
causing obstruction and dilatation of the vessels leading 
to collection of chylous material in cyst-like struct res. 
The cysts, when overdistended, may rupture resulting 
in chylous ascites. Lymphangioleiomyomas can exhibit 
diurnal variation, (visualized by CT or sonography) 
with lesions increasing in size during the day. This 
phenomenon can be an aid in a differential diagnosis f 
a probable lymphangioleiomyoma with thick walls and 
no fluid, from other mass lesions such as a lymphoma 
or a sarcoma. 
Prognosis 
Lymphatic involvement (defined by the presence of 
adenopathy and/or lymphangioleiomyomas) in patients 
with LAM, is correlated with more severe lung disea 
assessed by computed tomography scans. 
Genes involved and proteins 
Note 
Serum levels of VEGF-D, a lymphangiogenic growth 
factor, are higher in patients with LAM than those in 
healthy volunteers. In addition, serum levels of VEGF-
D in patients with LAM who have 
lymphangioleiomyomas and adenopathy are higher 
than in patients without lymphangioleiomyomas. LAM 
lung nodules demonstrate immunoreactivity for VEGF-
D. Because of these findings and reported observations 
of LAM cell clusters in lymphatic channels, it has been 
hypothesized that LAM-associated lymphangiogenesis, 
driven by VEGF-D, may account for the dissemination 
of LAM cells through the shedding of LAM cell 
clusters into the lymphatic system. 
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